Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.

Shi P, Zha J, Guo X, Chen F, Fan Z, Huang F, Meng F, Liu X, Feng R, Xu B.

Pharmacogenomics. 2013 Jan;14(1):17-23. doi: 10.2217/pgs.12.182.

PMID:
23252945
2.

Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.

Wiernik PH, Banks PL, Case DC Jr, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB.

Blood. 1992 Jan 15;79(2):313-9.

3.

[Improved treatment results in children with AML: Results of study AML-BFM 93].

Creutzig U, Berthold F, Boos J, Fleischhack G, Gadner H, Gnekow A, Graubner U, Henze G, Hermann J, Imbach P, Jürgens H, Kabisch H, Körholz D, Niemeyer CM, Reinhardt D, Reiter A, Ritter J, Spaar HJ, Zimmermann M; AML-BFM-Studien-Gruppe.

Klin Padiatr. 2001 Jul-Aug;213(4):175-85. German.

PMID:
11528551
5.

Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.

Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R.

Blood. 2011 Feb 24;117(8):2358-65. doi: 10.1182/blood-2010-03-273243. Epub 2010 Aug 6.

6.

A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia.

Wiernik PH, Case DC Jr, Periman PO, Arlin ZA, Weitberg AB, Ritch PS, Todd MB.

Semin Oncol. 1989 Feb;16(1 Suppl 2):25-9. No abstract available.

PMID:
2928807
7.

Anthracycline drugs and MDR expression in human leukemia.

Pogliani EM, Belotti D, Rivolta GF, Maffè PF, Corneo G.

Cytotechnology. 1996;19(3):229-35.

PMID:
8862011
8.

A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.

Masaoka T, Ogawa M, Yamada K, Kimura K, Ohashi Y.

Semin Hematol. 1996 Oct;33(4 Suppl 3):12-7.

PMID:
8916311
9.

A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.

Vogler WR, Velez-Garcia E, Omura G, Raney M.

Semin Oncol. 1989 Feb;16(1 Suppl 2):21-4. No abstract available.

PMID:
2648581
10.

Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.

Wiedower E, Jamy O, Martin MG.

Anticancer Res. 2015 Nov;35(11):6287-90.

PMID:
26504064
11.

High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.

Baer MR, Christiansen NP, Frankel SR, Brunetto VL, Mrózek K, Bloomfield CD, Herzig GP.

Semin Oncol. 1993 Dec;20(6 Suppl 8):6-12.

PMID:
7507264
12.

[Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].

Qin T, Xu Z, Zhang Y, Lin Y, Ru K, Fang L, Zhang H, Pan L, Hu N, Qu S, Wang J, Xing R, Xiao Z.

Zhonghua Xue Ye Xue Za Zhi. 2016 Feb;37(2):94-9. doi: 10.3760/cma.j.issn.0253-2727.2016.02.002. Chinese.

PMID:
27014976
13.

A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.

Reiffers J, Huguet F, Stoppa AM, Molina L, Marit G, Attal M, Gastaut JA, Michallet M, Lepeu G, Broustet A, Pris J, Maraninchi D, Hollard D, Fabères C, Mercier M, Hurteloup P, Danel P, Tellier Z, Berthaud P.

Leukemia. 1996 Mar;10(3):389-95.

PMID:
8642852
14.
15.

Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.

Liu H, Fu R, Li L, Wang G, Song J, Ruan E, Wang H, Wu Y, Wang X, Ding K, Shao Z.

Clin Drug Investig. 2017 Feb;37(2):167-174. doi: 10.1007/s40261-016-0469-9.

PMID:
27722823
16.

Risk-adapted induction and consolidation therapy in adults with de novo AML aged </= 60 years: results of a prospective multicenter trial.

Heil G, Krauter J, Raghavachar A, Bergmann L, Hoelzer D, Fiedler W, Lübbert M, Noens L, Schlimok G, Arnold R, Kirchner H, Ganser A.

Ann Hematol. 2004 Jun;83(6):336-44. Epub 2004 Mar 18.

PMID:
15034758
17.
18.

MDR1 RNA expression as a prognostic factor in acute myeloid leukemia: an update.

Gsur A, Zöchbauer S, Götzl M, Kyrle PA, Lechner K, Pirker R.

Leuk Lymphoma. 1993 Dec;12(1-2):91-4.

PMID:
7909245
19.

Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA.

Petti MC, Mandelli F.

Semin Oncol. 1989 Feb;16(1 Suppl 2):10-5. No abstract available.

PMID:
2928805
20.

Supplemental Content

Support Center